Compare · BRTX vs MTBC
BRTX vs MTBC
Side-by-side comparison of BioRestorative Therapies Inc. (BRTX) and CareCloud Inc. (MTBC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BRTX and MTBC operate in Managed Health Care (Health Care), so they compete in similar markets.
- MTBC is the larger of the two at $78.8M, about 13.5x BRTX ($5.9M).
- BRTX has hit the wire 5 times in the past 4 weeks while MTBC has been quiet.
- BRTX has more recent analyst coverage (1 ratings vs 0 for MTBC).
- Company
- BioRestorative Therapies Inc.
- CareCloud Inc.
- Price
- $0.23+2.72%
- $3.10+13.14%
- Market cap
- $5.9M
- $78.8M
- 1M return
- -26.90%
- -
- 1Y return
- -86.27%
- -
- Industry
- Managed Health Care
- Managed Health Care
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 5
- 0
- Recent ratings
- 1
- 0
BioRestorative Therapies Inc.
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100 that has completed Phase 1 clinical trials is a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate, which is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue (BAT). In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
CareCloud Inc.
CareCloud, Inc., a healthcare information technology (IT) company, provides a suite of cloud-based solutions and related business services to healthcare providers and hospitals primarily in the United States. It operates through two segments, Healthcare IT and Practice Management. The company's Software-as-a-Service platform includes revenue cycle management, practice management, electronic health record, business intelligence, telehealth, and patient experience management solutions, as well as complementary software tools and business services for medical groups and health systems. It serves physicians, nurses, nurse practitioners, physician assistants, and other clinicians that render bills for their services. The company was formerly known as MTBC, Inc. and changed its name to CareCloud, Inc. in March 2021. CareCloud, Inc. was founded in 1999 and is headquartered in Somerset, New Jersey.
Latest BRTX
- BioRestorative Therapies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform
- SEC Form POS AM filed by BioRestorative Therapies Inc.
- SEC Form DEF 14A filed by BioRestorative Therapies Inc.
- BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform
- SEC Form PRE 14A filed by BioRestorative Therapies Inc.
- BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease
- SEC Form 10-K filed by BioRestorative Therapies Inc.
- BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease
- BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026
Latest MTBC
- Garcia Nathalie Grey converted options into 4,278 shares and covered exercise/tax liability with 1,283 shares, increasing direct ownership by 38% to 10,808 units (SEC Form 4)
- SEC Form 4 filed by Roth Norman
- SEC Form 4 filed by Haq Mahmud Ul
- SEC Form 4 filed by Chaudhry A Hadi
- Roth Norman converted options into 7,000 shares and covered exercise/tax liability with 2,450 shares, increasing direct ownership by 5% to 94,425 units (SEC Form 4)
- Busquet Anne converted options into 12,500 shares, increasing direct ownership by 6% to 238,888 units (SEC Form 4)
- Korn Bill converted options into 7,500 shares, increasing direct ownership by 5% to 160,383 units (SEC Form 4)
- Munter Cameron converted options into 12,500 shares, increasing direct ownership by 8% to 176,500 units (SEC Form 4)
- Daly John N converted options into 12,500 shares, increasing direct ownership by 24% to 64,250 units (SEC Form 4)
- Sharnak Lawrence Steven converted options into 12,500 shares, increasing direct ownership by 21% to 71,500 units (SEC Form 4)